Best of ASCO - 2014 Annual Meeting

 

Welcome

Mesothelioma

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A feasibility study of induction pemetrexed plus cisplatin followed by pleurectomy/decortication for malignant pleural mesothelioma (Japan Mesothelioma Interest Group 1101 Trial).

Seiki Hasegawa

8518

A phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM).

Antoinette J. Wozniak

e20061

Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.

Susana Cedres

e20062

Association of BAP1 alterations with malignant pleural mesothelioma treated with trimodality therapy.

Marjorie Glass Zauderer

8552

Immune gene signatures and integrative spatially-resolved digital profiling of prognostic biomarkers for mesothelioma.

Sarah Elizabeth Church

e20071

Malignant pleural mesothelioma (MPM) genomic profile in the randomized phase II RAMES Study.

Maria Pagano

8547

Oral vinorelbine as a second-line chemotherapy option in advanced malignant pleural mesothelioma.

Raul Rogelio Trejo Rosales

e20073

Outcome of neo-adjuvant chemotherapy in 225 surgical candidates with malignant pleural mesothelioma.

Nobuyuki Kondo

8548

Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM).

Deepti Venkatraman

8549

Prognostic value of tumor infiltrating lymphocytes in epithelioid malignant pleural mesothelioma.

Michael Adashek

e20064

Radiological response patterns in the phase 2 STELLAR trial of TTFields with chemotherapy for first-line treatment of malignant pleural mesothelioma (MPM).

Federica Grosso

8551

Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance).

Arkadiusz Z. Dudek

8517

Survival impact of thoracic cavity reduction during neoadjuvant chemotherapy in patients undergoing surgery for malignant pleural mesothelioma.

Ayumi Kuroda

e20067

Survival meta-analysis from fifteen years of a standard systemic therapy in malignant pleural mesothelioma.

Joseph S. Friedberg

e20066

The combined treatment of 150 kHz tumor treating fields (TTFields) and cisplatin or pemetrexed inhibits mesothelioma cells in vitro and in vivo.

Uri Weinberg

e20069

Therapeutic targeting of polyamines in malignant pleural mesothelioma xenograft models.

James C. M. Ho

e20060

Treatment outcomes in malignant pleural mesothelioma: A single center experience of systemic therapies and biomarkers.

Adithya Balasubramanian

e20070